CytoMed Therapeutics Limited (GDTC) said its exclusively licensed induced pluripotent stem cell-based technology has been granted a patent by the China National Intellectual Property Administration. The patent titled Methods and Kits for Generating Mimetic Innate Immune Cells from Pluripotent Stem Cells covers technologies to derive synthetic ?d NKT cells for the treatment of various types of cancers including hematological malignancies and solid tumors. The company noted that this asset is currently under preclinical development.
Peter Choo, Chairman of CytoMed, said: "Now this iPSC-based technology has been granted patent in China and Japan. Such progress further expands current patent portfolio to three countries, consisting of and including patents granted in the US and China for our licensed allogeneic chimeric antigen receptor gamma delta T cell technology which is expected to start phase I clinical trial in Singapore soon.""
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.